Yervoy
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 14, 2025
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for ...
APRIL 9, 2025
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of ...
NOVEMBER 27, 2024
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
AACR Report: More Immuno Rx Strategies for Advanced Melanoma
Washington—Combining checkpoint inhibitors yields an overall survival (OS) benefit in advanced melanoma, ...
JUNE 12, 2017
Checkpoint Inhibitors Advancing in Multiple GI Cancers
Immunotherapy with checkpoint inhibitors, specifically agents targeting programmed death-1 (PD-1), are advancing in ...
MAY 31, 2017
Bringing Immunotherapy For Melanoma to the Front Line
After working for Chevron Lubricants for 33 years as a laboratory chemist, Tom Bell was happy to retire in early ...
OCTOBER 19, 2016
